Dr. Tsutomu Une is a Graduate of Hokkaido University School of Veterinary Medicine and holds a PhD in Microbiology.

Dr. Une joined Daiichi Pharmaceutical Company, Limited, in April 1970, going on to hold many important managerial positions over his career. He was appointed to the Board of Daiichi in June 1999 and subsequently served as Managing Director for various functions from October 2002 to June 2006, at which time he was promoted to Representative Senior Managing Director, Global Corporate Strategy.

Daiichi Sankyo was established in 2005, through the merger of two leading Japanese pharmaceutical companies, Daiichi Pharmaceutical Company Ltd. and Sankyo Company Limited. From September 2005 to June 2013, Dr. Une served on the Daiichi Sankyo board of directors as Senior Executive Officer in charge of global corporate strategy. In July 2013, Dr. Une became a Daiichi Sankyo Corporate Advisor.

In December 2008, Dr. Une was appointed as a Director on the board of Ranbaxy Laboratories Limited, a subsidiary of Daiichi Sankyo, and served as its Chairman till March 2015.

In June 2016, Dr. Une resigned from Daiichi Sankyo and joined Houlihan Lokey (former GCA Corporation), an M&A advisor company, as Senior Corporate Advisor. Dr. Une is also serving as an External Board Member or Corporate Advisor for few companies in the healthcare arena, including Ayumi Pharmaceutical Holdings.